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54 Poster Session IHCT co-morbidity index scores, disease status, donor source, and
acute and chronic GVHD, similar risks for developing hypothy-
roidism were observed between the two types of conditioning reg-
imens (relative risk for MA 1.6 [95% CI, 0.4–5.8] vs. RIC).
Female gender was the only factor predictive for hypothyroidism
(relative risk 4.5 [95% CI, 1.1–18.0] vs. males). In conclusion, hypo-
thyroidism is relatively infrequent in adult allogeneic HCT survi-
vors. At least in the first few years post-HCT, RIC is associated
with similar risks for hypothyroidism as MA conditioning.142
HIGH PREVALENCE OF IRON OVERLOAD IN ADULT SURVIVORS OF AL-
LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
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Iron overload is a well recognized complication of transfusion de-
pendent anemias. A large number of allogeneic hematopoietic cell
transplant (HCT) recipients receive red blood cell (RBC) transfu-
sions and pre-HCT serum ferritin has been reported to be an inde-
pendent predictor for early transplant related mortality. However,
the prevalence of iron overload in long-term allogeneic transplant
survivors is not known. We report a cross-sectional study of iron
overload in this population. Adult allogeneic HCT recipients
were eligible if they: (1) had survived for $12 months from their
transplant, (2) had no active infections, (3) had no active flare of
chronic graft-versus-host disease, and (4) had no contraindication
for magnetic resonance imaging (MRI) scan. Patients who con-
sented for participation were screened with serum ferritin (normal
range 10–300 ng/mL), and those with serum ferritin .1000 ng/
mL underwent R2 MRI of the liver to measure liver iron concentra-
tion (LIC, normal range 0.17–1.8 mg/g dry tissue) using the Ferri-
Scan technology, a highly sensitive and specific technique for
measuring hepatic iron content (St Pierre et al, Blood 2005, 105:
855). Iron overload was defined as LIC above the normal range
(.1.8 mg/g). Forty eight patients were enrolled and were a median
of 27 (range, 12–151) months from HCT. All were RBC transfusion
independent at the time of study enrollment. Median age was 49
(range, 24–69) years and 54% were males. The most common indi-
cations for HCT were acute leukemia (44%) and non-Hodgkin’s
lymphoma (31%). Eighteen patients had serum ferritin .1000
ng/mL (median 1516 [range, 1003–7311]); of these 17 had iron
overload on MRI (median LIC 7.5 (range, 2.8–28.3) mg/g), with
an overall prevalence rate of 35% (95% confidence intervals [CI],
22–51%). Clinically significant iron overload (LIC .5 mg/g) was
present in 11 patients (23% [95% CI, 12–37%]). LIC level on
MRI was only moderately correlated with serum ferritin level (r 5
0.49 [95% CI, 0.10–0.88]) and transferrin saturation level (r 5
0.55 [95% CI, 0.13–0.97]). In conclusion, iron overload is a frequent
late complication of allogeneic HCT. Serum ferritin is a good initial
screening test but it may not predict the level of hepatic iron content
and may not be useful by itself for identifying clinically significant
iron overload. More studies are needed to determine the natural his-
tory and treatment of iron overload in allogeneic HCT survivors.
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PRE-TRANSPLANT PULMONARY FUNCTION AND DAY 100 NON-RE-
LAPSE MORTALITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION
Basu, S.K.1, Liesveld, J.L.1, Trawick, D.R.2, Fernandez, D.3,
Nichols, D.1, Fisher, S.G.3 1University of Rochester, Rochester, NY;
2University of Rochester, Rochester, NY; 3University of Rochester,
Rochester, NY.
This study’s purpose was to evaluate the association between pul-
monary function, as measured by the diffusion capacity of the lung
for carbon monoxide (DLCO), before hematopoietic stem cell
transplantation (HSCT) and non-relapse mortality (NRM) at 100
days post-transplant. The rationale was that DLCO, as an early in-
dicator of lung disease or as a measure of pre-existing systemic en-
dothelial damage, might be a predictor of NRM.
Methods: This was a retrospective cohort study of all patients
undergoing their first HSCT at the University of Rochester be-
tween 1995 and 2004. NRM at 100 days (Day100NRM) was the pri-
mary outcome. DLCO, as percent predicted, corrected for
hemoglobin, was the main independent variable. The chi-square
test, Mantel-Haenszel test of trend, and analysis of variance were
used for categorical, ordinal, and continuous variables respectively
in bivariate analyses. Logistic regression was used for multivariate
analysis. Results: Data regarding DLCO, mortality, and patient
characteristics were available from 677 (95%) patients. By 100
days, 59 subjects died without having a relapse. Day100NRM was
8.5% (95% confidence interval: 6.4, 10.8%). Pulmonary complica-
tions (27%), graft-versus-host disease (15%), and multi-organ fail-
ure (14%) were the most frequent causes of Day100NRM. On
crude analysis, using DLCO in quartiles, there was a statistically
significant association (chi-square p 5 0.0179) and dose response
relationship (trend test p 5 0.0023) between DLCO and
Day100NRM. Of multiple variables analyzed, only race, smoking
status, diagnosis, body mass index, forced expiratory volume at
one second, forced vital capacity, serum alkaline phosphatase, and
serum albumin, had a statistically significant association with
DLCO and were included in multivariate testing. In the final mul-
tivariate model, low DLCO, low serum albumin, and type of cancer
diagnosis remained significantly associated with Day100NRM. The
odds ratio for DLCO was 1.442 (95% confidence interval: 1.103,
1.885), using DLCO in quartiles as an ordinal variable. Patients
in the lowest quartile of DLCO were almost three-times (odds ratio
5 2.99) as likely as patients in the highest quartile of DLCO to ex-
perience Day100NRM. Conclusions: There was a statistically sig-
nificant association and a dose-response relationship between pre-
transplant DLCO and Day100NRM. These results suggest that
the DLCO may be helpful at the time of the pre-transplant evalua-
tion in predicting risk of Day100NRM.144
FREQUENCY OF ABNORMAL FINDINGS DETECTED BY COMPREHENSIVE
EVALUATION AT ONE YEAR AFTER HEMATOPOIETIC CELL TRANSPLAN-
TATION
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Moravec, C.1, Carpenter, P.A.1, Martin, P.J.1, Flowers, M.E.D.1
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Medical records of 118 adults (88% of eligible patients alive with-
out relapse) who returned for evaluation at one year after allogeneic
hematopoietic cell transplantation (HCT) in 2005 were reviewed in
order to document the frequency of abnormal findings and to assess
the value of routine long-term follow-up (LTFU) assessments after
HCT. Most (n5 102, 86%) spent 2–3 days in Seattle for testing and
consultation, while 16 (14%) brought results of diagnostic testing
performed elsewhere. The cohort included 69 (58%) men and 49
women (42%), 47 (40%) who received reduced intensity condition-
ing, 62 (53%) with unrelated donors, 105 (89%) who received
growth-factor mobilized blood cells, and 18 (15%) who had second
transplants. Sixteen additional patients were alive at 1 year without
known recurrent malignancy who did not return for evaluation.
There were no statistically significant differences in the age, gender,
